DIRS.INFO The most relevant business & tech news

☆ Stocks making the biggest moves premarket: CrowdStrike, Merck, PayPal, JetBlue and more
▼ + stars: | 2024-07-30 | by ( Brian Evans | ) www.cnbc.com time to read: +6 min

Revenue of $695 million was also higher than the $686 million expected. Adjusted earnings of 5 cents per share topped the loss of 2 cents per share forecasted by analysts polled by FactSet. Additionally, Howmet increased its quarterly dividend to 8 cents per share from 5 cents per share, to be payable Aug. 26. JetBlue — Shares jumped 4% after the airline said adjusted earnings per share was 8 cents for the second quarter. Analysts expected a profit of $2.80 per share on revenue of $1.18 billion, according to StreetAccount.

Persons: Woodward, FactSet, LSEG, Archer, Gamble —, Leidos, StreetAccount, — CNBC's Michelle Fox, Hakyung Kim, Lisa Kailai Han, Alex Harring, Jesse Pound, Fred Imbert, John Melloy Organizations: CNBC, Delta Airlines, Microsoft, FactSet, Inc, —, Technology, Merck —, pharma, Semiconductor, Bank of America, Pfizer —, Pfizer, Varonis Systems, Howmet Aerospace, Corning, LSEG, Daniels, Midland, JetBlue —, Revenue, PayPal —, PayPal, Procter, Gamble, U.S . Pentagon Locations: FactSet .

☆ Swiss pharma giant Roche to accelerate Wegovy rival drugs after positive trial data
▼ + stars: | 2024-07-29 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +2 min

Swiss pharmaceutical giant Roche said Monday it is accelerating the development of its Wegovy rival weight loss drugs following promising early stage trial data. However, in an FT interview published earlier Monday, CEO Thomas Schinecker indicated that the firm's first obesity drug could come to market "significantly faster than people are expecting," potentially by 2028. Both CT-388 and CT-996 were acquired as part of Roche's purchase of U.S. biotech company Carmot Therapeutics, which completed in January. The promising results could see Roche emerge as a potential rival to obesity drug pioneers Novo Nordisk and Eli Lilly. Schinecker told CNBC last week that he expects the company to eventually offer a suite of obesity medications.

Persons: Roche, Nordisk's Wegovy, Eli Lilly, Thomas Schinecker, Teresa Graham, Roche's, Schinecker Organizations: Nordisk's, CNBC, Roche Pharmaceuticals, Carmot Therapeutics, Novo Nordisk Locations: U.S

☆ Here are JPMorgan's top drug stock picks into earnings
▼ + stars: | 2024-07-29 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

JPMorgan is eyeing a few drug manufacturers ahead of their earnings reports as investors continue to sell out of major technology firms. This backdrop has analyst Chris Schott reviewing JPMorgan's top pharmaceutical and biotechnology stocks, which includes "stories that have clear upside potential to longer-term estimates" like Eli Lilly and Merck. Eli Lilly Pharmaceutical company Eli Lilly made the list. Schott said the firm is somewhat below consensus Wall Street estimates for Eli Lilly heading into second-quarter results on Aug. 8. LLY YTD mountain Eli Lilly stock.

Persons: Johnson, Merck —, Chris Schott, Eli Lilly, Merck, Schott, —, Regeneron Organizations: JPMorgan, Dow Jones, Johnson, Merck, US Major Pharma, Schott, FactSet, Pharmaceuticals Locations: Mounjaro, Novo

☆ Stocks making the biggest moves before the bell: McDonald's, Tesla, Stellantis and more
▼ + stars: | 2024-07-29 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

McDonald's — Shares were down slightly in the premarket after the fast food giant reported second-quarter results that missed analyst expectations . Bristol-Myers Squibb — The pharma stock shed 1.5% following a downgrade to underweight from equal weight at Barclays. This call comes after Bristol-Myers Squibb issued better-than-expected earnings and raised its full-year guidance on Friday. Tesla — The electric vehicle maker advanced 1.5% after bring crowned the top pick U.S. auto stock by Morgan Stanley analyst Adam Jonas. The Marvel movie raked in more than $200 million during its opening weekend, making it the strongest debut on record for an R-rated film.

Persons: McDonald's, Olin, Myers Squibb, Myers, Tesla, Morgan Stanley, Adam Jonas, Stellantis, Microstrategy, —, Samantha Subin, Sarah Min, Michelle Fox, Fred Imbert Organizations: JPMorgan, Technologies, Guggenheim, Myers, pharma, Barclays, Myers Squibb, Bristol, Ford, Deutsche Bank, Chrysler, Dodge, Disney, Marvel Locations: Bristol, Monday's premarket

☆ China says relations with Japan at 'critical stage'
▼ + stars: | 2024-07-27 | by ( ) www.cnbc.com time to read: +2 min

Relations between China and Japan are at a critical stage, Chinese Foreign Minister Wang Yi told his Japanese counterpart on Friday as the pair discussed thorny issues including Japanese nationals detained in China, food import bans and semiconductor curbs. "China-Japan relations are currently at a critical point: advance or be left behind," Wang told Kamikawa, according to a readout of the talks issued by the Chinese foreign ministry. It is hoped that the Japanese side will establish an objective and correct perception of China and pursue a positive and rational policy towards China." In their first one-to-one talks in eight months, Kamikawa strongly urged the lifting of import restrictions Beijing imposed on Japan food products in the wake of the Fukushima water release. She also called for the early release of Japan detainees in China.

Persons: Wang Yi, Wang, Japan's Yoko Kamikawa, Kamikawa Organizations: Southeast, ASEAN, Saturday's East Asia Summit, ASEAN Regional Forum, Japan, Astellas Pharma Locations: China, Japan, Laos, Saturday's, Beijing, Tokyo

☆ Beyond Novo and Eli Lilly: Watch these biotech and weight loss drug names, fund manager says
▼ + stars: | 2024-07-26 | by ( Weizhen Tan | ) www.cnbc.com time to read: +3 min

Weight loss drugs have drawn investor interest and shaken up other sectors in the past year or so. Novo Nordisk and Eli Lilly were two early winners of this trend, as their drugs dominate the weight loss drug market. Yuri Khodjamirian, fund manager at Tema ETFs, said both companies are a "very powerful duopoly." They're a lot more risky than the bigger ones who already have drugs on the market," Khodjamirian said. Tema ETFs offers actively managed exchange-traded funds, with a focus on health care and life sciences.

Persons: Eli Lilly, Yuri Khodjamirian, Goldman Sachs, Khodjamirian, Roche Organizations: Novo Nordisk, Tema, CNBC, Zealand Pharma, Viking Therapeutics, Tema Oncology, Mental Health Locations: Tema

☆ You've heard of pretty privilege, but 'ugly privilege' may have its perks too
▼ + stars: | 2024-07-26 | by ( Lindsay Dodgson | ) www.businessinsider.com time to read: +6 min

But what about "ugly privilege"? A TikToker called Sarah posted a video this week, which has amassed 159,000 views at the time of writing, where she explained why she thought she had "ugly privilege" and what it meant. "But when I say I have ugly privilege, it's not that I necessarily think I'm an ugly individual," Sarah said. She continued: "But when I say I have ugly privilege, what I mean by that is men, in general, don't mind me attractive." Underlying sexismRegardless of the "privilege" of being deemed ugly or pretty, women are disproportionately scrutinized for their looks and are acutely aware of this scrutiny.

Persons: —, Sarah, it's, I've, that's, Lucas Botzen, Botzen, Melissa Weaver, hadn't, Weaver, Daniela Herrera, Chilcutt Organizations: Service, Business, Johns Hopkins Carey Business School, University of, Sinclair Pharma, Allies, Recruiting

☆ CNBC Pro Talks: From weight loss drugs to AI winners, CIO set to reveal his top stocks
▼ + stars: | 2024-07-16 | by ( ) www.cnbc.com time to read: +2 min

Weight loss drugs and artificial intelligence have been dominating headlines, with investors betting that stocks in both categories have big potential upside. On Wednesday's Pro Talks , CNBC's Senior Technology Correspondent Arjun Kharpal will ask Tema ETFs' Yuri Khodjamirian how to best invest in these areas and more. Tema ETFs offers actively managed ETFs, with a focus on healthcare and life sciences. Before Tema ETFs, Khodjamirian spent over a decade at Majedie Asset Management, overseeing U.K. and global portfolios. Click here to join CNBC Pro Talks on Wednesday, July 17, at 7 a.m.

Persons: Arjun Kharpal, Yuri Khodjamirian, Eli Lilly, he'll, Khodjamirian Organizations: Tema, Novo Nordisk, pharma, Majedie Asset Management, Income, CNBC, Nvidia, Scotiabank Locations: Tema, —, U.S, U.K, India

☆ Sean 'Diddy' Combs hires top NYC defense lawyer Marc Agnifilo to fight possible federal sex-trafficking charges
▼ + stars: | 2024-07-10 | by ( Laura Italiano | ) www.businessinsider.com time to read: +5 min

Marc Agnifilo addresses reporters in 2019 outside federal court in Brooklyn, where he represented NXIVM cult leader Keith Raniere. Timothy A. Clary/Getty ImagesAgnifilo, a former state and federal prosecutor in Manhattan, said he and co-counsel Teny Geragos are in regular communication with federal prosecutors. Combs has not spoken with prosecutors, added Agnifilo, now at Agnifilo Intrater. Alberto E. Rodriguez/Getty ImagesThe video corroborated allegations of violence in the R&B singer's lawsuit against Combs and Bad Boy Entertainment. Brafman repped Combs again in the leadup to the Ventura lawsuit.

Persons: —, Sean, Diddy, Combs, Marc Agnifilo, Pharma Bro, Martin Shkreli, Goldman Sachs, Roger Ng, Keith Raniere, Agnifilo, Cassie Ventura, There's, Timothy A, Clary, Teny Geragos, Ventura, Lionsgate's, Alberto E, Rodriguez, I'm, Roberta Intrater, Jennifer Lopez, repped, Benjamin Brafman, Uncle Benny, Brafman repped Combs, Brafman, Ben Organizations: Service, Pharma, Business, Southern, of, CNN, Bad Boy Entertainment, Adria, Times Square, Brafman, Associates, Ventura, US Locations: Manhattan, of New York, Los Angeles, Miami, Brooklyn, New York, Florida, Ventura

☆ States and Creditors for Purdue Pharma Threaten Sacklers With Gush of Lawsuits
▼ + stars: | 2024-07-09 | by ( Jan Hoffman | ) www.nytimes.com time to read: +1 min

Purdue itself is supporting a proposal by a group of its creditors to sue individual Sacklers for transferring billions of dollars out of the company and into family trusts and overseas holding companies. The motions, some filed and others in the planning stage, are part of intense maneuvering to pressure the Sacklers to settle thousands of opioid lawsuits brought years ago against them and their company. If one isn’t struck by Sept. 9, thousands of lawsuits against the company and family members, which have been on hold for nearly five years, are likely to proceed. The Supreme Court’s ruling, on June 27, effectively dissolved an agreement negotiated between the Sacklers and Purdue, the manufacturer of the prescription opioid OxyContin, and states, local and tribal governments as well as individuals and other groups. Under that plan, the Sackers had agreed to contribute $6 billion — but only on the condition that they be granted protection from all civil lawsuits involving opioid claims.

Persons: Sackler Organizations: Purdue

☆ Read Biden’s Letter to Congressional Democrats
▼ + stars: | 2024-07-08 | by ( ) www.nytimes.com time to read: +4 min

I have had extensive conversations with the leadership of the party, elected officials, rank and file members, and most importantly, Democratic voters over these past 10 days or so. Believe me, I know better than anyone the responsibility and the burden the nominee of our party carries. The voters of the Democratic Party have voted. I feel a deep obligation to the faith and the trust the voters of the Democratic Party have placed in me to run this year. The voters - and the voters alone - decide the nominee of the Democratic Party.

Persons: JOSEPH R, BIDEN, Donald Trump, I've, Trump Organizations: JR, Democratic, Democratic Party, Big Pharma, MAGA Republicans, Trump Locations: America

☆ Stop worrying and learn to love the triumph of Big Tech over everything
▼ + stars: | 2024-07-07 | by ( Jim Cramer | ) www.cnbc.com time to read: +9 min

We don't say they have a secular wind at their backs. We don't say: Apple's business is much better than we thought. They keep coming back to one main point: You can't have these companies dominate without something bad happening to the stock market. Let me present a different, factual manifesto: The companies with these amazing gains are companies that just don't stop inventing. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: Eli Lilly, Joe Biden, Biden, Lilly, —, Tesla, Elon Musk, Jim Cramer's, Jim Cramer, Jim Organizations: Amazon, Microsoft, Apple, Nvidia, Nasdaq, pharma, Novo Nordisk, National Football League, YouTube, Web Services, Costco, Walmart, Jim Cramer's Charitable, CNBC, Facebook, Google Locations: Lilly

In this next term, I’m going to make sure we got to — straighten out the tax system. STEPHANOPOULOS: The number of Americans who think you’re too old to serve has doubled since 2020. STEPHANOPOULOS: I’ve — I’ve questioned him and his allies as persistently as any journalist has. We have — I mean, I’m not seen what you’re — you’re proposing. He may bring me down, he may.”STEPHANOPOULOS: Mr. President, I’ve never seen a president 36 percent approval get re-elected.

Persons: Biden, George Stephanopoulos, GEORGE STEPHANOPOULOS, BIDEN, Nancy Pelosi, you’ve, I’m, You’ve, I’ve, ”, “, who’ve, what’s Biden, George, — BIDEN, —, “ You’re, Walter Reed, Madeleine Albright, Netanyahu, They’ll, ” BIDEN, Putin, it’s, I’d, Donald Trump, You’re, It’s, he’s, you’re, That’s, “ That’s, hadn’t, Nothing’s, They’re, Trump, — I’ve, oth, Hoover, Mark Warner, We’ve, Mark’s, Chuck Schumer, Hakeem Jeffries, “ We’re, Jim Clyburn, they’re, Almighty, “ Joe, ” I’d, Almighty’s, Hakeem, “ Oh, what’s, I’ll, George . Organizations: ABC, The New York Times, National Security Council, New York Times, The Washington Post, Street, NATO, Big Pharma, BIDEN, Putin, AUKUS, Senate, CBS Poll, NBC, Electoral College, Washington Post, Democratic Party, House Democrats, Senate Democrats Locations: Europe, Camp David, North Carolina, —, Georgia, The, England, Pacific, Ukraine, South Korea, United States, It’s, New York, China

☆ Anant Ambani, Radhika Merchant wedding: Everything you need to know about India’s wedding of the year
▼ + stars: | 2024-07-03 | by ( Rhea Mogul | ) edition.cnn.com time to read: +11 min

Extravagant pre-wedding celebrations have already sent Indian media into a frenzy and social media feeds are abuzz over what’s to come. Anant Ambani and Radhika Merchant at their pre-wedding celebrations in Jamnagar, Gujarat, India on March 1, 2024. The Ambani pre-wedding celebrations had elaborate floral arrangements. Actor Ranveer Singh and his wife and actor Deepika Padukone pose for a photo during the pre-wedding celebrations earlier this year. Coordinating with Merchant, Ambani also wore a custom black suit designed by Wun, encrusted with jewels.

Persons: Anant Ambani, Radhika Merchant, Mark Zuckerberg, Bill Gates, partygoers, Katy Perry, Andrea Bocelli, Mukesh, Nita Ambani –, Reuters Ambani, Mukesh Ambani, Ambani, Anant, Viren Merchant, Nita, Manish Malhotra, ”, Merchant, “, Radhika, Mangal Utsav, Vishnu, Nita Ambani, Manish Malhotra Malhotra, Ranveer Singh, Deepika Padukone, Malhotra, Sabyasachi Mukherjee, Tarun Tahiliani, lehenga, Manish Malhotra Ambani’s, Rohit Bal, Lorraine Schwartz, Versace, Blake Lively, Robert Wun, ” Mareesha, Salman Khan, Ram Charan, Shah Rukh Khan, Aamir Khan, Narendra Modi, ” Parikh, Vanessa Almeida, Jamnagar Organizations: CNN, Backstreet Boys, Convention, Reliance Industries, Reuters, Bloomberg, Brown University, Reliance, pharma, Viren, Encore Healthcare, New York University, Vogue, sangeet, Sangeet, Merchant, All India Traders Locations: what’s, Jamnagar, Europe, Mumbai, Gujarat, India, Jamnagar ., Bharatnatyam, Agra, Uttar Pradesh, Hong Kong, Goa

☆ Two Appearances, Two Starkly Different Bidens
▼ + stars: | 2024-06-28 | by ( Michael D. Shear | ) www.nytimes.com time to read: 1 min

And then you think he’ll stop there? Do you think he’ll stop when — if he takes Ukraine? What do you think happens to Poland? What do you think happens to those NATO countries? He did beat Medicare.

Persons: I’ve, Biden, Trump Organizations: NATO, Pharma Locations: Ukraine, Poland, Belarus

☆ Gen Zers and millennials are willing to go on summer vacation at all costs. Literally.
▼ + stars: | 2024-06-28 | by ( Dan Defrancesco | ) www.businessinsider.com time to read: +7 min

In today's big story, we're looking at how young people are booking their summer vacations , finances be damned. AdvertisementSurveys from Credit Karma, Bankrate, and Bank of America show Gen Zers and millennials are willing to go on summer vacation at all costs… literally. Almost half of millennials surveyed (47%) were willing to take on debt to fund their travel plans, with Gen Z not far behind (42%). AdvertisementAlmost a quarter of young people surveyed by Credit Karma expected to rack up $2,000 in debt this summer. And about 10% of that group were willing to push it even further, surpassing $4,000 in summer debt.

Persons: —, Joe Biden's, Donald Trump, Rebecca Zisser, John Towfighi, Zers, millennials, Gen, it's, you'll, Credit Karma, Klaus Vedfelt, That's, Rob Chisholm, Alyssa Powell, he's, Joseph Stiglitz, Trump, Stiglitz, Justin Sullivan, Chelsea Jia Feng, ChatGPT, Mark Zuckerberg, Sundar Pichai, — livestreaming, Twitch's Dan Clancy, Tyler Le, Gigi, Sackler, Ebrahim Raisi, Dan DeFrancesco, Jordan Parker Erb, Hallam Bullock, Annie Smith, Amanda Yen Organizations: Service, Biden, Business, Credit, Bank of America, Getty, SEC, Purdue Pharma, Dua Lipa, Coldplay Locations: Amalfi, Vegas, ., Glastonbury, New York, London

☆ Supreme Court blocks Purdue Pharma bankruptcy settlement
▼ + stars: | 2024-06-27 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailSupreme Court blocks Purdue Pharma bankruptcy settlementCNBC's Eamon Javers reports the latest news on the Supreme Court.

Persons: CNBC's Eamon Javers Organizations: Purdue Pharma

☆ Supreme Court Rejects Liability Shield at Center of Purdue Pharma Settlement
▼ + stars: | 2024-06-27 | by ( Abbie Vansickle | ) www.nytimes.com time to read: +1 min

The Supreme Court ruled on Thursday that members of the wealthy Sackler family cannot be shielded from lawsuits over their role in the opioid crisis as part of a bankruptcy settlement that would channel billions of dollars to victims and their families. In a 5-to-4 decision, written by Justice Neil M. Gorsuch, a majority of the justices held that the federal bankruptcy code does not authorize a liability shield for third parties in bankruptcy agreements. Justice Gorsuch was joined by Justices Clarence Thomas, Samuel A. Alito Jr., Amy Coney Barrett and Ketanji Brown Jackson. In a strongly worded dissent, Justice Brett M. Kavanaugh wrote that the “decision is wrong on the law and devastating for more than 100,000 opioid victims and their families.” He was joined by Chief Justice John G. Roberts Jr. and Justices Sonia Sotomayor and Elena Kagan. The decision jeopardizes a carefully negotiated settlement Purdue and the Sacklers had reached in which members of the family promised to give up to $6 billion to states, local governments, tribes and individuals to address a devastating public health crisis.

Persons: Sackler, Justice Neil M, Gorsuch, Clarence Thomas, Samuel A, Alito Jr, Amy Coney Barrett, Ketanji Brown Jackson, Brett M, Kavanaugh, John G, Roberts Jr, Sonia Sotomayor, Elena Kagan Organizations: Chief, Purdue

☆ The $7 billion Purdue bankruptcy plan giving the Sacklers immunity from more lawsuits gets nixed by Supreme Court
▼ + stars: | 2024-06-27 | by ( Jack Newsham | ) www.businessinsider.com time to read: +3 min

Read previewThe US Supreme Court has struck down a $7 billion bankruptcy plan for Purdue Pharma that would have protected the Sackler family from further lawsuits — a ruling that could mean "chaos" for other big legal liability cases. The Sackler family, which ran Purdue, agreed to provide up to $6 billion in funding in exchange for immunity from further legal action. Anne Andrews, a leading bankruptcy lawyer for victims, predicted tumult if the Supreme Court struck down the Purdue plan in an interview with Business Insider ahead of the decision. Related stories"The U.S. Supreme Court got it right — billionaire wrongdoers should not be allowed to shield blood money in bankruptcy court," he said. Its plan, which would provide $2.5 billion, is currently on appeal in the Third Circuit Court of Appeals.

Persons: —, Sackler, Anne Andrews, William Tong, wrongdoers, Johnson, Leigh O'Dell, Beasley Allen, J's Organizations: Service, Purdue Pharma, Purdue, Business, Sackler, U.S, Supreme, Justice Department, J, Boy Scouts of Locations: Boy Scouts of America

☆ Purdue Opioid Settlement on Verge of Collapse After Supreme Court Ruling
▼ + stars: | 2024-06-27 | by ( Jan Hoffman | ) www.nytimes.com time to read: +1 min

The hard-fought settlement of thousands of lawsuits against Purdue Pharma was close to capsizing on Thursday, after the Supreme Court rejected liability protections for the company’s owners. The ruling effectively prevents the release of billions of dollars that could help alleviate the ravages of opioid addiction. The future of the cases, some of which are a decade old, is now in limbo, as states, local governments, tribes and more than 100,000 individuals who sued the company, best-known for its prescription painkiller OxyContin, figure out next moves. The court effectively upended the settlement by striking down a provision that Purdue’s owners, members of the billionaire Sackler family, had insisted upon: immunity from all current and future opioid lawsuits in return for payments of up to $6 billion to plaintiffs. In a statement, Purdue called the decision “heart-crushing,” because the settlement had been agreed to by an overwhelming majority of plaintiffs.

Persons: Sackler Organizations: Purdue Pharma, Purdue Locations: capsizing

☆ Supreme Court rejects multibillion-dollar Purdue Pharma opioid settlement that shielded Sackler family
▼ + stars: | 2024-06-27 | by ( John Fritze | ) edition.cnn.com time to read: +3 min

As the nation continues to grapple with the opioid epidemic, the Sackler family had agreed to pay $6 billion to families and states as part of an agreement to wind down Purdue Pharma, the maker of OxyContin. In exchange, the Sackler family would be immunized from future civil liability claims. Those supporting the bankruptcy argued the yearslong process had gone on long enough and was unlikely to yield additional money from the Sackler family. The vast majority of known current opioid victims and their families supported the agreement. But the Justice Department said it was a raw deal for victims – particularly potential future victims.

Persons: Sackler, Neil Gorsuch, ” Gorsuch, “, ” Kavanaugh, ”, John Roberts, Sonia Sotomayor, Elena Kagan Organizations: Washington CNN, Chief, Congress, Purdue Pharma, Department Locations: New York

The iShares U.S. Pharmaceuticals ETF (IHE) is up 9% since July 2015, when it hit a fresh all-time high. All of the back-and-forth movement since 2015 has produced what could be a monstrous bullish pattern. But we're trying to capture a major breakout from an area that's done next to nothing in nearly a decade. INVA, on the other hand, bottomed in March 2023, and just recently broke out of a large inverse head & shoulders pattern. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR.

Persons: IHE, Eli Lilly, Johnson, JNJ, MRK, Frank Cappelleri Organizations: U.S . Pharmaceuticals, IHE, Merck, CNBC, NBC UNIVERSAL Locations: U.S, LLY

☆ Biden Cabinet officials roll out new plans to cut costs of living ahead of Trump debate
▼ + stars: | 2024-06-26 | by ( Rebecca Picciotto | ) www.cnbc.com time to read: +1 min

U.S. President Joe Biden delivers remarks alongside Treasury Secretary Janet Yellen and Commerce Secretary Gina Raimondo during a Cabinet Meeting at the White House on June 06, 2023 in Washington, DC. President Joe Biden's Cabinet will wrap up a barnstorming tour Thursday after two weeks on the road, touting the administration's economic accomplishments ahead of the Democratic incumbent's first debate against former President Donald Trump. In the 10 days leading up to Thursday's debate, the White House organized 29 public events, featuring more than a dozen top administration officials to promote Biden's economic agenda, a White House official said in a memo announcing the blitz. Not anymore," Neera Tanden, White House domestic policy advisor, said in the release. "Thanks to President Biden's economic plan, the American economy is strong and resilient, with robust economic growth in recent quarters," she said in a speech Monday.

Persons: Joe Biden, Janet Yellen, Gina Raimondo, Joe Biden's, Donald Trump, Lael Brainard, Pete Buttigieg, Neera Tanden, Yellen, Biden's Organizations: White House, Democratic, White, National Economic, Transportation, Seniors Locations: Washington , DC, Georgia , Nevada , Pennsylvania, Michigan, White, Minnesota, American

☆ Cramer’s Stop Trading: Alnylam Pharma
▼ + stars: | 2024-06-24 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCramer’s Stop Trading: Alnylam PharmaCNBC’s Jim Cramer explains why he is keeping an eye on shares of Alnylam Pharma.

Persons: Jim Cramer Organizations: Alnylam, Alnylam Pharma

☆ Weight loss drug contender Zealand Pharma jumps 23% on trial results
▼ + stars: | 2024-06-21 | by ( Jenni Reid | ) www.cnbc.com time to read: +1 min

Vials on the Wegovy line at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on Friday, March 8, 2024. LONDON — Shares of Denmark's Zealand Pharma popped nearly 23% in Friday morning deals, notching a record high after an early-stage study of its weight loss drug challenger produced positive results. Petrelintide was "judged to be safe and well tolerated at all dose levels" and the results provided "robust support" for its potential as an alternative to GLP-1 receptor agonist-based therapies for weight management, Zealand Pharma said in a release. GLP-1RA-based treatments include Ozempic, the diabetes drug produced by fellow Danish pharmaceutical firm Novo Nordisk , which has exploded in popularity globally for its weight-loss effects. Soaring demand for Ozempic and obesity drug Wegovy have propelled Novo Nordisk to become Europe's most valuable company.

Persons: Petrelintide Organizations: Novo Nordisk, Denmark's Zealand Pharma, Zealand Pharma Locations: Hillerod, Denmark, Danish

Search resuls for: "PHARMA"

25 mentions found